Secondary Response of Ovarian Tumors to Topotecan Treatment
- 1 June 1998
- journal article
- case report
- Published by Elsevier in Gynecologic Oncology
- Vol. 69 (3) , 258-259
- https://doi.org/10.1006/gyno.1998.5013
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Camptothecin and Its AnalogsAnnals of the New York Academy of Sciences, 1996
- Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.Journal of Clinical Oncology, 1996
- Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.Journal of Clinical Oncology, 1996
- Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.Journal of Clinical Oncology, 1996
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of Clinical Oncology, 1991